Login to Your Account

Pfizer to Pay Medivation $225M Up Front in Dimebon Deal

By Catherine Hollingsworth

Thursday, September 4, 2008
Drugmaker Pfizer Inc. will pay a hefty $225 million up front to Medivation Inc. in a deal to co-develop and market Dimebon, the biotech company's experimental drug for Alzheimer's and Huntington's disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription